KR20110062528A - 나린제닌을 포함하는 항균용 렌즈 - Google Patents
나린제닌을 포함하는 항균용 렌즈 Download PDFInfo
- Publication number
- KR20110062528A KR20110062528A KR1020090119277A KR20090119277A KR20110062528A KR 20110062528 A KR20110062528 A KR 20110062528A KR 1020090119277 A KR1020090119277 A KR 1020090119277A KR 20090119277 A KR20090119277 A KR 20090119277A KR 20110062528 A KR20110062528 A KR 20110062528A
- Authority
- KR
- South Korea
- Prior art keywords
- naringenin
- pseudomonas
- lens
- antimicrobial
- contact lens
- Prior art date
Links
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 title claims abstract description 194
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 title claims abstract description 193
- 235000007625 naringenin Nutrition 0.000 title claims abstract description 193
- 229940117954 naringenin Drugs 0.000 title claims abstract description 193
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 52
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 64
- 241000894006 Bacteria Species 0.000 claims abstract description 43
- 239000004599 antimicrobial Substances 0.000 claims abstract description 9
- 241000589516 Pseudomonas Species 0.000 claims description 35
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 11
- 238000013268 sustained release Methods 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- 238000002834 transmittance Methods 0.000 claims description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 6
- 240000000560 Citrus x paradisi Species 0.000 claims description 5
- 241000168225 Pseudomonas alcaligenes Species 0.000 claims description 4
- 241000520869 Pseudomonas anguilliseptica Species 0.000 claims description 4
- 241000589781 Pseudomonas oleovorans Species 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 241001240954 Escherichia albertii Species 0.000 claims description 3
- 241000588720 Escherichia fergusonii Species 0.000 claims description 3
- 240000005979 Hordeum vulgare Species 0.000 claims description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 3
- 241000857755 Pseudomonas argentinensis Species 0.000 claims description 3
- 241000855937 Pseudomonas borbori Species 0.000 claims description 3
- 241000520873 Pseudomonas citronellolis Species 0.000 claims description 3
- 241000588717 Shimwellia blattae Species 0.000 claims description 3
- WNXTZVMMNCCZTP-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate 5-hydroxy-2-methylpent-2-enoic acid Chemical compound OCCC=C(C(=O)O)C.C(C(=C)C)(=O)OCCO WNXTZVMMNCCZTP-UHFFFAOYSA-N 0.000 claims description 2
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 claims description 2
- 241000588732 Atlantibacter hermannii Species 0.000 claims description 2
- 241000588733 Pseudescherichia vulneris Species 0.000 claims description 2
- 241001148192 Pseudomonas flavescens Species 0.000 claims description 2
- 241000589755 Pseudomonas mendocina Species 0.000 claims description 2
- 241000204735 Pseudomonas nitroreducens Species 0.000 claims description 2
- 241000589630 Pseudomonas pseudoalcaligenes Species 0.000 claims description 2
- 241000520900 Pseudomonas resinovorans Species 0.000 claims description 2
- 241000218901 Pseudomonas straminea Species 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 239000000470 constituent Substances 0.000 abstract description 4
- 208000030533 eye disease Diseases 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 231100000135 cytotoxicity Toxicity 0.000 description 21
- 230000003013 cytotoxicity Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 239000003755 preservative agent Substances 0.000 description 17
- 239000012153 distilled water Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 13
- 238000011109 contamination Methods 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000004087 cornea Anatomy 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 206010023332 keratitis Diseases 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000000795 conjunctiva Anatomy 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011342 resin composition Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010015946 Eye irritation Diseases 0.000 description 5
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 231100000013 eye irritation Toxicity 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960003376 levofloxacin Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100029269 Coatomer subunit alpha Human genes 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 3
- 229930019673 naringin Natural products 0.000 description 3
- 229940052490 naringin Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007447 staining method Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- IDHVLSACPFUBDY-QCDLPZBNSA-N xenin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CN=CN1 IDHVLSACPFUBDY-QCDLPZBNSA-N 0.000 description 3
- 108010006643 xenin 25 Proteins 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 229920002306 Glycocalyx Polymers 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004517 glycocalyx Anatomy 0.000 description 2
- 229940107702 grapefruit seed extract Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000005641 methacryl group Chemical group 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000009993 protective function Effects 0.000 description 2
- 229930187593 rose bengal Natural products 0.000 description 2
- 229940081623 rose bengal Drugs 0.000 description 2
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 2
- VDNLFJGJEQUWRB-UHFFFAOYSA-N rose bengal free acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C21 VDNLFJGJEQUWRB-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- -1 silver ions Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 206010011033 Corneal oedema Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000011482 antibacterial activity assay Methods 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000012662 bulk polymerization Methods 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 201000005533 central corneal ulcer Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000882 contact lens solution Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 201000004778 corneal edema Diseases 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001057 purple pigment Substances 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- ZBNARPCCDMHDDV-HVMBLDELSA-N trypan blue sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S(O)(=O)=O)S(O)(=O)=O)C)=C(O)C2=C1N ZBNARPCCDMHDDV-HVMBLDELSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
- G02C7/049—Contact lenses having special fitting or structural features achieved by special materials or material structures
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Eyeglasses (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Abstract
Description
Claims (10)
- 제 1 항에 있어서, 상기 나린제닌은 자몽(grapefruit)으로부터 추출된 물질인 것을 특징으로 하는 항균용 렌즈.
- 제 1 항에 있어서, 상기 렌즈는 50-99 중량% 2-하이드로시에틸메타클레이드(2-hydroxyethylmethacrylate), 0.1-10 중량% 메타크릴산(methacrylic acid), 0.1-10 중량% N-비닐 피롤리돈(N-vinyl pyrrolidone) 및 0.1-20 중량% 나린제닌을 포함하는 것을 특징으로 하는 항균용 렌즈.
- 제 1 항에 있어서, 상기 나린제닌을 포함하는 항균용 렌즈는 가시광선 영역인 400-780 nm에서 100% 광 투과도를 나타내는 것을 특징으로 하는 항균용 렌즈.
- 제 1 항에 있어서, 상기 렌즈는 렌즈로부터 나린제닌이 서방형(sustained release)으로 용출(elution) 또는 분비되어 항균 활성을 나타내는 것을 특징으로 하는 항균용 렌즈.
- 제 5 항에 있어서, 상기 나린제닌의 용출량 또는 분비량은 3-6 x 10-7 g/일(day)인 것을 특징으로 하는 항균용 렌즈.
- 제 1 항에 있어서, 상기 균은 슈도모나스 에루지노사(pseudomonas aeruginosa), 슈도모나스 알카리제네스(pseudomonas alcaligenes), 슈도모나스 앙귈리셉티카(pseudomonas anguilliseptica), 슈도모나스 아르젠티넨시스(pseudomonas argentinensis), 슈도모나스 보르보리(pseudomonas borbori), 슈도모나스 시트로넬로리스(pseudomonas citronellolis), 슈도모나스 플라베센 스(pseudomonas flavescens), 슈도모나스 멘도시나(pseudomonas mendocina), 슈도모나스 니트로레두센스(pseudomonas nitroreducens), 슈도모나스 올레오보란스(pseudomonas oleovorans), 슈도모나스 슈도알카리제네스(pseudomonas pseudoalcaligenes), 슈도모나스 레시노보란스(pseudomonas resinovorans) 또는 슈도모나스 스트라미네아(pseudomonas straminea)균인 것을 특징으로 하는 항균용 렌즈.
- 제 1 항에 있어서, 상기 균은 에스케리키아 콜리(Escherichia coli), 에스케리키아 알베르티(Escherichia albertii), 에스케리키아 블라태(Escherichia blattae), 에스케리키아 퍼구소니 (Escherichia fergusonii), 에스케리키아 헤르만니(Escherichia hermannii) 또는 에스케리아 불너리스(Escherichia vulneris)균인 것을 특징으로 하는 항균용 렌즈.
- 제 1 항에 있어서, 상기 렌즈는 안과용 콘택트렌즈인 것을 특징으로 하는 항균용 렌즈.
- 제 9 항에 있어서, 상기 렌즈는 소프트 콘택트렌즈인 것을 특징으로 하는 항 균용 렌즈.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090119277A KR20110062528A (ko) | 2009-12-03 | 2009-12-03 | 나린제닌을 포함하는 항균용 렌즈 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090119277A KR20110062528A (ko) | 2009-12-03 | 2009-12-03 | 나린제닌을 포함하는 항균용 렌즈 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20110062528A true KR20110062528A (ko) | 2011-06-10 |
Family
ID=44396697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090119277A KR20110062528A (ko) | 2009-12-03 | 2009-12-03 | 나린제닌을 포함하는 항균용 렌즈 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20110062528A (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101953474B1 (ko) * | 2017-09-14 | 2019-02-28 | 서울과학기술대학교 산학협력단 | 콘택트렌즈 및 그 제조방법 |
KR20190025288A (ko) | 2017-09-01 | 2019-03-11 | (주)지에프씨생명과학 | 항산화, 항염 및 주름개선 활성을 갖는 황숙종 유래의 화합물을 함유하는 화장료 조성물 |
CN109988738A (zh) * | 2019-05-22 | 2019-07-09 | 南京农业大学 | 一种耐盐促生菌菌株b9及其应用 |
-
2009
- 2009-12-03 KR KR1020090119277A patent/KR20110062528A/ko active Search and Examination
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190025288A (ko) | 2017-09-01 | 2019-03-11 | (주)지에프씨생명과학 | 항산화, 항염 및 주름개선 활성을 갖는 황숙종 유래의 화합물을 함유하는 화장료 조성물 |
KR101953474B1 (ko) * | 2017-09-14 | 2019-02-28 | 서울과학기술대학교 산학협력단 | 콘택트렌즈 및 그 제조방법 |
CN109988738A (zh) * | 2019-05-22 | 2019-07-09 | 南京农业大学 | 一种耐盐促生菌菌株b9及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Martins et al. | Efficacy of red propolis hydro-alcoholic extract in controlling Streptococcus mutans biofilm build-up and dental enamel demineralization | |
de Freitas Fernandes et al. | Efficacy of denture cleansers on Candida spp. biofilm formed on polyamide and polymethyl methacrylate resins | |
EP1861069B2 (en) | Contact lens, method for producing same, and pack for storage and maintenance of a contact lens | |
Topete et al. | Dual drug delivery from intraocular lens material for prophylaxis of endophthalmitis in cataract surgery | |
Vivero-Lopez et al. | Phosphorylcholine-based contact lenses for sustained release of resveratrol: design, antioxidant and antimicrobial performances, and in vivo behavior | |
KR100878053B1 (ko) | 나린진을 함유한 항균 콘택트렌즈 및 그의 제조방법 | |
KR20110062528A (ko) | 나린제닌을 포함하는 항균용 렌즈 | |
de Azevedo et al. | Disinfectant effects of Brazilian green propolis alcohol solutions on the Staphylococcus aureus biofilm of maxillofacial prosthesis polymers | |
CN110078794A (zh) | 一种抗菌肽及其应用 | |
Kim et al. | Antioxidant and physical properties of dual-networked contact lenses containing quercetin using chitosan and alginate | |
KR101953474B1 (ko) | 콘택트렌즈 및 그 제조방법 | |
KR102025818B1 (ko) | 천연 항균제 및 이의 제조방법 | |
CA2771325C (fr) | Une composition alimentaire antibacterienne comprenant un extrait de vaccinium macrocarpon et un extrait de propolis | |
EP3157582B1 (en) | Protection of contact lenses from microbial contamination caused by handling | |
KR101553685B1 (ko) | 항균성의 하이드로겔 콘택트렌즈 및 그 제조방법 | |
Vermeltfoort et al. | Bacterial transmission from contact lenses to porcine corneas: an ex vivo study | |
Kwak et al. | Antibacterial Effect of Naringin‐containing Soft Contact Lens | |
Hammadi et al. | Detection of the inhibition activity of alcoholic extract of green tea leaves (Camellia sinensis) and zinc oxide nanoparticles against few bacteria and fungi species isolated from eyes infection | |
CN102688479A (zh) | 预防干眼症的组合物、包括其的眼贴膜及该眼贴膜的制备方法 | |
CN113577302A (zh) | 多糖多肽偶联物在治疗感染性角膜炎中的用途 | |
Kedcharoen et al. | Microbial biofilm formation on vanillin incorporated surgical obturator resin | |
EP4102292A1 (en) | Contact lens and manufacturing method therefor | |
Alalwan | Combining nanofabrication with natural antimicrobials to control denture plaque | |
Hammo et al. | Evaluation of the resistance of CuO-coated contact lenses to bacterial contamination | |
Kıvanç et al. | Do Lactobacillus rhamnosus-originated probiotic and parabiotic have inhibitory effects on intraocular lens biofilm? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20091203 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110728 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20120330 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20110728 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20120330 Comment text: Decision to Refuse Application |
|
PX0601 | Decision of rejection after re-examination |
Comment text: Decision to Refuse Application Patent event code: PX06014S01D Patent event date: 20120530 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20120430 Comment text: Decision to Refuse Application Patent event code: PX06011S01I Patent event date: 20120330 Comment text: Notification of reason for refusal Patent event code: PX06013S01I Patent event date: 20110728 |
|
J201 | Request for trial against refusal decision | ||
PJ0201 | Trial against decision of rejection |
Patent event date: 20120730 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20120530 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Patent event date: 20120330 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20120910 Appeal identifier: 2012101007016 Request date: 20120730 |
|
J801 | Dismissal of trial |
Free format text: REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20120730 Effective date: 20120910 |
|
PJ0801 | Rejection of trial |
Patent event date: 20120910 Patent event code: PJ08011S01D Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision) Decision date: 20120910 Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2012101007016 Request date: 20120730 |